Ifosfamide: chemotherapy with new promise and new problems for the urologist.
Ifosfamide, a chemotherapeutic agent, offers new hope as well as new problems for the uro-oncologist. The "good news" is that this drug is achieving marked benefits in treating resistant testis tumors and may even hold hope for patients with renal cell carcinoma. The "bad news" is that a price must be paid in toxicity--predominantly a severe and restrictive hemorrhagic cystitis. A breakthrough is the finding that oral administration of acetylcysteine (Mucomyst) may, to a large extent, prevent this untoward side effect.
D000111:Acetylcysteine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003556:Cystitis / Q000139:chemically induced / Q000517:prevention & control; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D007069:Ifosfamide / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D013736:Testicular Neoplasms / Q000188:drug therapy*
D003520:Cyclophosphamide; D007069:Ifosfamide; D000111:Acetylcysteine